some cancers by conferring an invasive phenotype. As well as facilitating metastasis, EMT is 23 thought to generate cancer stem cells and contribute to therapy resistance. The EMT pathway is 24 therefore of great therapeutic interest in the treatment of cancer and could potentially be targeted 25 either to prevent tumor dissemination in patients at high risk of developing metastatic lesions or to 26 eradicate existing metastatic cancer cells in patients with more advanced disease. This review 27 discusses approaches for the design of EMT-based therapies in cancer, summarizes evidence for 28 some of the proposed EMT targets and reviews the potential advantages and pitfalls of each 29 approach.
31
Targeting EMT in cancer 32 Epithelial-mesenchymal transition (EMT) describes the process whereby cells shed their epithelial 33 properties and adopt a more mesenchymal and invasive phenotype [1, 2] . EMT is characterized by 34 the loss of cell-cell adhesions and apicobasal polarity, and the transition to a cell type with a more 35 spindle-like morphology that is capable of invading the extracellular matrix [1, 2] . Molecularly,
36
EMT involves the downregulation of epithelial-type proteins (e.g., the adherens junction protein E- [1, 2] . This phenomenon was first described in the context of embryonic 40 development [3] , in which primary EMT events play an integral role in processes such as 41 gastrulation and neural crest formation. In the adult, EMT is implicated in wound healing, transforming growth factor β (TGFβ) show enhanced resistance to cisplatin and paclitaxel [14] .
74
EMT is also associated with resistance to tyrosine kinase inhibitors in hepatocellular and non-small 75 cell lung carcinomas [18, 19] , and resistance to hormonal therapy in breast cancers [20] . limitations; in all cases the pharmacological targets so far identified go beyond the markers 92 classically associated with EMT [4] . 
Targeting mesenchymal-epithelial transition (MET)

221
MET is an emerging concept in cancer research that describes the reversion of mesenchymal-like in the reversion to a cell type more suited for proliferation and colonization of the secondary organ. 
Concluding remarks
285
There are a variety of potential pharmacological approaches to exploit the EMT process to prevent Red indicates gene silencing approach Blue indicates pharmacological approach Arrows indicate either an inhibitory (↓), promoting (↑) or neutral (↔) effect on either EMT markers or migration/invasion. a Examples of proposed EMT targets, where the specific protein target has been identified and assessed for its role in EMT in cancer cells b Up to three specific and/or non-specific pharmacological inhibitors listed for each target c Ion channel and kinase (EC 2) * Indicates a pharmacological inhibitor that was used in at least one EMT study listed in reference column COX2, cyclooxygenase 2; CXCR4, chemokine (C-X-C motif) receptor 4; EGFR, epidermal growth factor receptor; Erk2, extracellular signal-regulated kinase 2; ETAR, endothelin receptor type A; FAK, focal adhesion kinase; FUT4, fucosyltransferase 4; GPCR, G-protein coupled receptor; IGF1R, insulin-like growth factor type 1 receptor; ILK, integrin linked kinase; KCNN4, potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4; MMP3, matrix metalloproteinase-3; MMP9, matrix metalloproteinase-9; α7-nAChR, α7 nicotinic acetylcholine receptor; P2X5, purinergic receptor X5; PIMT, protein L-isoaspartyl O-methyltransferase; SHP2, Src homology phosphotyrosine phosphatase 2; SMO, smoothened; TG2, tissue transglutaminase; TGFβR1, transforming growth factor β receptor type 1; TRPM7, transient receptor potential cation channel, subfamily M, member 7; uPAR, urokinase plasminogen activator receptor. 327 328 and colonize the secondary organ(s). Epithelial-mesenchymal transition (EMT) is a process 
